Skip to main content
EastWest Bioscience Inc. logo

EastWest Bioscience Inc. — Investor Relations & Filings

Ticker · EAST.H ISIN · CA27783V1076 TSXV Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2022-10-28 Regulatory Filings
Country CA Canada
Listing TSXV EAST.H

About EastWest Bioscience Inc.

https://www.eastwestbioscience.com/

EastWest Bioscience Inc. is a vertically integrated wellness company operating on a seed-to-sale model. It specializes in the sourcing, manufacturing, branding, marketing, and distribution of multiple lines of premium hemp and CBD consumer goods. The company owns and operates retail and manufacturing subsidiaries, including an award-winning natural health retail unit. Its manufacturing capabilities include custom blends and production runs for top-quality wellness products, supported by Health Canada certified facilities and infrastructure designed for global distribution in the consumer health market.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-10-28 English
News release - English.pdf
Regulatory Filings
2022-08-12 English
News release - English.PDF
Major Shareholding Notification Classification · 100% confidence The document is a press release titled 'Early Warning Report in accordance with National Instrument 62-103' and details a direct acquisition of shares by a company officer, Ms. Ciska Asriel, who is COO and CFO. It specifies the number of shares owned before and after the transaction and the percentage ownership. This matches the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels. The document is short and focused on share acquisition by an insider, not a full report or financial statement. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2022-08-11 English
Interim financial statements/report – English.pdf
Regulatory Filings
2022-06-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2022-06-29 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from EastWest Bioscience reporting a material increase in earnings recognition due to the deconsolidation of a subsidiary. It discusses financial events such as a financing round, loss of control of a subsidiary, and recognition of gains. It also provides operational updates on the subsidiary and background information about the company. The document does not contain detailed financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is more of a financial update and operational announcement. The length is 7092 characters, which is sufficient for a detailed announcement but not a full financial report. The content focuses on financing activities and changes in capital structure (loss of control of subsidiary, financing round). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-04-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.